International Study to Predict Optimized Treatment for Depression (iSPOT-D), a randomized clinical trial: Rationale and protocol

Trials

Volumn 12, Issue , 2011, Pages

  Williams, Leanne M ^a,b   Rush, A J ^c   Koslow, Stephen H ^a,d   Wisniewski, Stephen R ^e   Cooper, Nicholas J ^f,i   Nemeroff, Charles B ^g   Schatzberg, Alan F ^h   Gordon, Evian ^b,f,i  

^a BRAINnet Foundation   (United States)

^b UNIVERSITY OF SYDNEY   (Australia)

^c DUKE NUS MEDICAL SCHOOL   (Singapore)

^d American Foundation for Suicide Prevention   (United States)

^e UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^f Brain Resource Ltd   (Australia)

^g UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^h STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁱ Brain Resource International Database   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; BRAIN DERIVED NEUROTROPHIC FACTOR; CATECHOL METHYLTRANSFERASE; ESCITALOPRAM; SEROTONIN 2A RECEPTOR; SERTRALINE; TRYPTOPHAN HYDROXYLASE; VENLAFAXINE; ANTIDEPRESSANT AGENT; CITALOPRAM; CYCLOHEXANOL DERIVATIVE; SEROTONIN UPTAKE INHIBITOR;

ADULT; ARTICLE; CLINICAL ASSESSMENT; COGNITION; DEPRESSION; DIFFUSION TENSOR IMAGING; DISTRESS SYNDROME; ELECTROENCEPHALOGRAPHY; EMOTIONALITY; EVENT RELATED POTENTIAL; FOLLOW UP; FUNCTIONAL MAGNETIC RESONANCE IMAGING; FUNCTIONAL STATUS; GENE EXPRESSION; GENOTYPE; HAMILTON SCALE; HEART RATE; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; METABOLOMICS; MULTICENTER STUDY (TOPIC); NUCLEAR MAGNETIC RESONANCE IMAGING; OPEN STUDY; OUTCOME ASSESSMENT; PATIENT SELECTION; PREDICTOR VARIABLE; PROSPECTIVE STUDY; PROTEOMICS; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; SELF REPORT; SINGLE NUCLEOTIDE POLYMORPHISM; SOCIAL INTERACTION; SYMPTOM; TELEPHONE; TREATMENT DURATION; TREATMENT RESPONSE; ADOLESCENT; AGED; AUSTRALIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DECISION SUPPORT SYSTEM; DRUG EFFECT; EMOTION; EUROPE; FEMALE; MALE; METHODOLOGY; MIDDLE AGED; MULTICENTER STUDY; NEUROPSYCHOLOGICAL TEST; NEW ZEALAND; PSYCHOLOGICAL ASPECT; PSYCHOLOGICAL RATING SCALE; RANDOMIZED CONTROLLED TRIAL; SOCIAL BEHAVIOR; TIME; TREATMENT OUTCOME; UNITED STATES;

ADOLESCENT; ADULT; AGED; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; AUSTRALIA; CITALOPRAM; COGNITION; CYCLOHEXANOLS; DECISION SUPPORT TECHNIQUES; DEPRESSIVE DISORDER, MAJOR; ELECTROENCEPHALOGRAPHY; EMOTIONS; EUROPE; FEMALE; HUMANS; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; NEW ZEALAND; PROSPECTIVE STUDIES; PSYCHIATRIC STATUS RATING SCALES; QUALITY OF LIFE; RESEARCH DESIGN; SEROTONIN UPTAKE INHIBITORS; SERTRALINE; SOCIAL BEHAVIOR; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES; YOUNG ADULT;

EID: 78650770457     PISSN: 17456215     EISSN: 17456215     Source Type: Journal    
DOI: 10.1186/1745-6215-12-4     Document Type: Article

References (75)

1. Greenberg PE, Stiglin LE, Finkelstein SN, Berndt ER. The economic burden of depression in 1990. J Clin Psychiatry 1993, 54:405-418.
2. Murray CJ, Lopez AD. Evidence-based health policy--lessons from the Global Burden of Disease Study. Science 1996, 274:740-743. 10.1126/science.274.5288.740, 8966556.
3. Kessler RC, Berglund P, Demler O, Jin R, Koretz D, Merikangas KR, Rush AJ, Walters EE, Wang PS, . National Comorbidity Survey Replication The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA 2003, 289:3095-3105. 10.1001/jama.289.23.3095, 12813115, National Comorbidity Survey Replication.
4. Simon GE, Von Korff M, Barlow W. Health care costs of primary care patients with recognized depression. Arch Gen Psychiatry 1995, 52:850.
5. Frank E, Karp JF, Rush AJ. Efficacy of treatments for major depression. Psychopharmacol Bull 1993, 29:457-475.
6. Depression Guideline Panel Clinical practice guideline. Number 5. Depression in primary care: volume 2. Treatment of major depression 1993, Rockville, MD: U.S. Department of Health and Human Services, Public Health Service, Agency for Health Care Policy and Research, AHCPR Publication No. 93-0551, Depression Guideline Panel.
7. Thase ME, Rush AJ. Treatment-resistant depression. Psychopharmacology: fourth generation of progress 1995, 1081-1097. New York: Raven Press, Bloom FE, Kupfer DJ.
8. American Psychiatric Association Practice guideline for major depressive disorder in adults. Am J Psychiatry 1993, 150(Suppl 4):1-2. American Psychiatric Association.
9. Rosenbaum JF, Fava M, Nierenberg AA, Sachs GS. Treatment-resistant mood disorders. Treatments of psychiatric disorders 2001, 1307-1384. Washington, DC: American Psychiatric Press, Inc, Gabbard GO, 3.
10. Fava M, Davidson KG. Definition and epidemiology of treatment-resistant depression. Psychiatr Clin North Am 1996, 19:179-200. 10.1016/S0193-953X(05)70283-5, 8827185.
11. Frank E, Prien R, Jarrett RB, Keller MB, Kupfer DJ, Lavori PW, Rush AJ, Weissman MM. Conceptualization and rationale for consensus definitions of terms in major depressive disorder. Remission, recovery, relapse and recurrence. Arch Gen Psychiatry 1991, 48:851-855.
12. Trivedi MH, Rush AJ, Wisniewski SR, Nierenberg AA, Warden D, Ritz L, Norquist G, Howland RH, Lebowitz B, McGrath PJ, Shores-Wilson K, Biggs MM, Balasubramani GK, Fava M, . STAR*D Study Team Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry 2006, 163:28-40. 10.1176/appi.ajp.163.1.28, 16390886, STAR*D Study Team.
13. Miller IW, Keitner GI, Schatzberg AJ, Klein DN, Thase ME, Rush AJ, Markowitz JC, Schlager DS, Kornstein SG, Davis SM, Harrison WM, Keller MB. The treatment of chronic depression, Part 3: psychosocial functioning before and after treatment with sertraline or imipramine. J Clin Psychiatry 1998, 59:608-619. 10.4088/JCP.v59n1108, 9862607.
14. Judd LL, Paulus MP, Wells KB. Socioeconomic burden of subsyndromal depressive symptoms and major depression in a sample of the general population. Am J Psychiatry 1996, 153:1411-1416.
15. Judd LL. The clinical course of unipolar major depressive disorders. Arch Gen Psychiatry 1997, 54:989-991.
16. Rush AJ, Trivedi MH. Treating depression to remission. Psychiatr Ann 1995, 25:704-705.
17. Van Londen L, Molenaar RP, Goekoop JG, Zwinderman AH, Rooijmans HG. Three- to 5-year prospective follow-up of outcome in major depression. Psychol Med 1998, 28:731-735. 10.1017/S0033291797006466, 9626729.
18. Sackeim HA, Prudic J, Devanand DP, Nobler MS, Lisanby SH, Peyser S, Fitzsimons L, Moody BJ, Clark J. A prospective, randomized, double-blind comparison of bilateral and right unilateral electroconvulsive therapy at different stimulus intensities. Arch Gen Psychiatry 2000, 57:425-434. 10.1001/archpsyc.57.5.425, 10807482.
19. Rush AJ, Fava M, Wisniewski SR, Lavori PW, Trivedi MH, Sackeim HA, Thase ME, Nierenberg AA, Quitkin FM, Kashner TM, Kupfer DJ, Rosenbaum JF, Alpert J, Stewart JW, McGrath PJ, Biggs MM, Shores-Wilson K, Lebowitz BD, Ritz L, Niederehe G, . STAR*D Investigators Group: for the STAR*D Investigators Group Sequenced Treatment Alternatives to Relieve Depression (STAR*D): Rationale and Design. Control Clin Trials 2004, 25:116-142. STAR*D Investigators Group: for the STAR*D Investigators Group.
20. Kraemer HC, Wilson GT, Fairburn CG, Agras WS. Mediators and moderators of treatment effects in randomized clinical trials. Arch Gen Psychiatry 2002, 59:877-883. 10.1001/archpsyc.59.10.877, 12365874.
21. Gordon E, Williams LML. Personalized Medicine and Integrative Neuroscience: towards consensus markers for disorders of brain health. Personalized Medicine, Healthcare and Integrative Neuroscience 2010, New York: Oxford University Press, Gordon E, Koslow SH.
22. Rush AJ. STAR*D: What have we learned?. Am J Psychiatry 2007, 164:201-204. 10.1176/appi.ajp.164.2.201, 17267779.
23. Joyce PR, Paykerl ES. Predictors of drug response in depression. Arch Gen Psychiatry 1989, 46(1):88-99.
24. Hennings JM, Owashi T, Binder EB, Horstmann S, Menke A, Kloiber S, Dose T, Wollweber B, Spieler D, Messer T, Lutz R, Künzel H, Bierner T, Pollmächer T, Pfister H, Nickel T, Sonntag A, Uhr M, Ising M, Holsboer F, Lucae S. Clinical characteristics and treatment outcome in a representative sample of depressed inpatients - Findings from the Munich Antidepressant Response Signature (MARS) project. J Psychiatr Res 2009, 43:215-229. 10.1016/j.jpsychires.2008.05.002, 18586274.
25. Rush AJ, Wisniewski SR, Warden D, Luther JF, Davis LL, Fava M, Nierenberg AA, Trivedi MH. Selecting Among Second-Step Antidepressant Medication Monotherapies, Predictive Value of Clinical, Demographic, or First-Step Treatment Features. Arch Gen Psychiatry 2008, 65(8):870-880. 10.1001/archpsyc.65.8.870, 18678792.
26. March JS, Silva SG, Compton S, Shaprio M, Califf R, Krishman R. The case for practical clinical trials in psychiatry. Am J Psychiatry 2005, 162:836-846. 10.1176/appi.ajp.162.5.836, 15863782.
27. Tunis SR, Stryer DB, Clancy CM. Practical trials: increasing the value of clinical research for decision making in clinical and health policy. JAMA 2003, 290:1624-1632. 10.1001/jama.290.12.1624, 14506122.
28. Williams LM, Gatt JM, Hatch A, Palmer DM, Nagy M, Rennie C, Cooper NJ, Morris C, Grieve S, Dobson-Stone C, Schofield P, Clark CR, Gordon E, Arns M, Paul RH. The INTEGRATE Model of emotion, thinking and self regulation: an application to the 'paradox of aging'. J Integr Neurosci 2008, 7(3):367-404. 10.1142/S0219635208001939, 18988298.
29. Gordon E. Integrative Neuroscience. Neuropsychopharmacology 2003, 28(Suppl 1):S2-8. 10.1038/sj.npp.1300136, 12827137.
30. Gordon E, Barnett KJ, Cooper N, Tran N, Williams LM. An 'integrative neuroscience' platform: application to profiles of negativity and positivity. J Integr Neurosci 2008, 7(3):345-366. 10.1142/S0219635208001927, 18988297.
31. Sheehan DV, Lecrubier Y, Harnett-Sheehan K, Janavs J, Weiller E, Keskiner A, Schinka J, Knapp E, Sheehan MF, Dunbar GC. Reliability and Validity of the MINI International Neuropsychiatric Interview (M.I.N.I.): According to the SCID-P. European Psychiatry 1997, 12:232-241.
32. Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, Hergueta T, Baker R, Dunbar GC. The Mini-International Neuropsychiatric Interview (M.I.N.I.): The development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 1998, 59(Suppl 20):22-33.
33. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960, 23:56-61. 10.1136/jnnp.23.1.56, 495331, 14399272.
34. Rush AJ, Carmody T, Reimitz PE. The Inventory of Depressive Symptomatology (IDS): Clinician (IDS-C) and self-report (IDS-SR) ratings of depressive symptoms. International Journal of Methods Psychiatric Research 2000, 9:45-59.
35. Rush AJ, Trivedi MH, Ibrahim HM, Carmody TJ, Arnow B, Klein DN, Markowitz JC, Ninan PT, Kornstein S, Manber R, Thase ME, Kocsis JH, Keller MB. The 16-item Quick Inventory of Depressive Symptomatology (QIDS) Clinician Rating (QIDS-C) and Self-Report (QIDS-SR): a psychometric evaluation in patients with chronic major depression. Biol Psychiatry 2003, 54:573-583. 10.1016/S0006-3223(02)01866-8, 12946886.
36. Trivedi MH, Rush AJ, Ibrahim HM, Carmody TJ, Biggs MM, Suppes T, Crismon ML, Shores-Wilson K, Toprac MG, Dennehy EB, Witte B, Kashner TM. The Inventory of Depressive Symptomatology, clinician rating (IDS-C) and self-report (IDS-SR), and the Quick Inventory of Depressive Symptomatology, clinician rating (QIDS-C) and self-report (QIDS-SR) in public sector patients with mood disorders: A psychometric evaluation. Psychol Med 2004, 34:73-82. 10.1017/S0033291703001107, 14971628.
37. Binder EB, Holsboer F. Pharmacogenomics and antidepressant drugs. Ann Med 2006, 38:82-94. 10.1080/07853890600551045, 16581694.
38. Choi MJ, Kang RH, Lim SW, Oh KS, Lee MS. Brain-derived neurotrophic factor gene polymorphism (Val66Met) and citalopram response in major depressive disorder. Brain Res 2006, 1118:176-182. 10.1016/j.brainres.2006.08.012, 16979146.
39. Paddock S, Laje G, Charney D, Rush AJ, Wilson AF, Sorant AJ, Lipsky R, Wisniewski SR, Manji H, McMahon FJ. Association of GRIK4 with Outcome of Antidepressant Treatment in the STAR*D Cohort. Am J Psychiatry 2007, 164:1181-1188. 10.1176/appi.ajp.2007.06111790, 17671280.
40. Binder EB, Salyakina D, Lichtner P, Wochnik GM, Ising M, Pütz B, Papiol S, Seaman S, Lucae S, Kohli MA, Nickel T, Künzel HE, Fuchs B, Majer M, Pfennig A, Kern N, Brunner J, Modell S, Baghai T, Deiml T, Zill P, Bondy B, Rupprecht R, Messer T, Köhnlein O, Dabitz H, Brückl T, Müller N, Pfister H, Lieb R, Mueller JC, Lõhmussaar E, Strom TM, Bettecken T, Meitinger T, Uhr M, Rein T, Holsboer F, Muller-Myhsok B. Polymorphisms in FKBP5 are associated with increased recurrence of depressive episodes and rapid response to antidepressant treatment. Nat Genet 2004, 36:1319-1325. 10.1038/ng1479, 15565110.
41. Nemeroff CB. Recent findings in the pathophysiology of depression. Am J Psychiatry 2008, 6:3-14.
42. Zanardi R, Benedetti F, Di Bella D, Catalano M, Smeraldi E. Efficacy of paroxetine in depression is influenced by a functional polymorphism within the promoter of the serotonin transporter gene. J Clin Psychopharmacol 2000, 20:105-107. 10.1097/00004714-200002000-00021, 10653220.
43. Tsai SJ, Cheng CY, Yu YW, Chen TJ, Hong CJ. Association study of a brain-derived neurotrophicfactor genetic polymorphism and major depressive disorders, symptomatology, and antidepressant response. Am J Med Genet B Neuropsychiatr Genet 2003, 123:19-22.
44. Villafuerte SM, Vallabhaneni K, Sliwerska E, McMahon FJ, Young EA, Burmeister M. SSRI response in depression may be influenced by SNPs in HTR1B and HTR1A. Psychiatr Genet 2009, 19(6):281-291. 10.1097/YPG.0b013e32832a506e, 2783179, 19829169.
45. Gatt JM, Nemeroff CB, Dobson-Stone C, Paul RH, Bryant RA, Schofield PR, Gordon E, Kemp AH, Williams LM. Interactions between BDNF Val66Met polymorphism and early life stress predict brain and arousal pathways to syndromal depression and anxiety. Mol Psychiatry 2009, 14(7):681-695. 10.1038/mp.2008.143, 19153574.
46. Lee BT, Ham BJ. Serotonergic genes and amygdala activity in response to negative affective facial stimuli in Korean women. Genes Brain Behav 2008, 7:899-905. 10.1111/j.1601-183X.2008.00429.x, 18826444.
47. Williams LM, Gatt JM, Schofield PR, Olivieri G, Peduto A, Gordon E. 'Negativity bias' in risk for depression and anxiety: brain-body fear circuitry correlates, 5-HTT-LPR and early life stress. Neuroimage 2009, 47(3):804-814. 10.1016/j.neuroimage.2009.05.009, 19446647.
48. Wisniewski SR, Rush AJ, Balasubramani GK, Trivedi MH, Nierenberg AA, . for the STAR*D Investigators Self-rated global measure of the frequency, intensity, and burden of side effects. J Psychiatr Pract 2006, 12(2):71-79. 10.1097/00131746-200603000-00002, 16728903, for the STAR*D Investigators.
49. World Health Organization Group Development of the World Health Organization WHOQOL-BREF quality of life assessment. Psychol Med 1998, 28:551-558. 10.1017/S0033291798006667, 9626712, World Health Organization Group.
50. Goldman HH, Skodol AE, Lave TR. Revising axis V for DSM-IV: a review of measures of social functioning. Am J Psychiatry 1992, 149:1148-1156.
51. Gross JJ, John OP. Individual differences in two emotion regulation processes: Implications for affect, relationships and well-being. J Pers Soc Psychol 2003, 85:348-362. 10.1037/0022-3514.85.2.348, 12916575.
52. Lovibond PF, Lovibond SH. Manual for the Depression Anxiety Stress Scales 1995, Sydney: Psychological Foundation, 2.
53. Lovibond PF. Long-term stability of Depression, Anxiety and Stress syndromes. J Abnorm Psychol 1998, 107:520-526. 10.1037/0021-843X.107.3.520, 9715586.
54. Cohen RA, Grieve S, Hoth KF, Paul RH, Sweet L, Tate D, Gunstad J, Stroud L, McCaffery J, Hitsman B, Niaura R, Clark CR, McFarlane A, Bryant R, Gordon E, Williams LM. Early life stress and morphometry of the adult anterior cingulate cortex and caudate nuclei. Biol Psychiatry 2006, 59(10):975-982. 10.1016/j.biopsych.2005.12.016, 16616722.
55. Williams LM, Mathersul D, Palmer DM, Gur RC, Gur RE, Gordon E. Explicit identification and implicit recognition of facial emotions: I. Age effects in males and females across 10 decades. J Clin Exp Neuropsychol 2009, 31(3):257-277. 10.1080/13803390802255635, 18720177.
56. Clark CR, Paul RH, Williams LM, Arns M, Fallahpour K, Handmer C, Gordon E. Standardized assessment of cognitive functioning during development and aging using an automated touchscreen battery. Arch Clin Neuropsychol 2006, 21(5):449-467. 10.1016/j.acn.2006.06.005, 16904862.
57. Gunstad J, Paul RH, Brickman AM, Cohen RA, Arns M, Roe D, Lawrence JJ, Gordon E. Patterns of cognitive performance in middle-aged and older adults: A cluster analytic examination. J Geriatr Psychiatry Neurol 2006, 19(2):59-64. 10.1177/0891988705284738, 16690989.
58. Williams LM, Simms E, Clark CR, Paul RH, Rowe D, Gordon E. The test-retest reliability of a standardized neurocognitive and neurophysiological test battery: "neuromarker". Int J Neurosci 2005, 115(12):1605-1630. 10.1080/00207450590958475, 16287629.
59. Paul RH, Lawrence J, Williams LM, Richard CC, Cooper N, Gordon E. Preliminary validity of "integneuro": a new computerized battery of neurocognitive tests. Int J Neurosci 2005, 115(11):1549-1567. 10.1080/00207450590957890, 16223701.
60. Paul RH, Gunstad J, Cooper N, Williams LM, Clark CR, Cohen RA, Lawrence JJ, Gordon E. Cross-cultural assessment of neuropsychological performance and electrical brain function measures: additional validation of an international brain database. Int J Neurosci 2007, 117(4):549-568. 10.1080/00207450600773665, 17365135.
61. Brickman AM, Zimmerman ME, Paul RH, Grieve SM, Tate DF, Cohen RA, Williams LM, Clark CR, Gordon E. Regional white matter and neuropsychological functioning across the adult lifespan. Biol Psychiatry 2006, 60(5):444-453. 10.1016/j.biopsych.2006.01.011, 16616725.
62. Zimmerman ME, Brickman AM, Paul RH, Grieve SM, Tate DF, Gunstad J, Cohen RA, Aloia MS, Williams LM, Clark CR, Whitford TJ, Gordon E. The relationship between frontal gray matter volume and cognition varies across the healthy adult lifespan. Am J Geriatr Psychiatry 2006, 14(10):823-833. 10.1097/01.JGP.0000238502.40963.ac, 17001022.
63. Grieve SM, Williams LM, Paul RH, Clark CR, Gordon E. Cognitive aging, executive function, and fractional anisotropy: a diffusion tensor MR imaging study. AJNR Am J Neurorad 2007, 28(2):226-235.
64. Hatch A, Madden S, Kohn MR, Clarke S, Touyz S, Gordon E, Williams LM. In first presentation adolescent anorexia nervosa, do cognitive markers of underweight status change with weight gain following a refeeding intervention?. Int J Eat Disord 2010, 43(4):295-306.
65. Liddell BJ, Paul RH, Arns M, Gordon N, Kukla M, Rowe D, Cooper N, Moyle J, Williams LM. Rates of Decline Distinguish Alzheimer's Disease and Mild Cognitive Impairment relative to Normal Aging: Integrating Cognition and Brain Function. J Integr Neurosci 2007, 6(1):141-174. 10.1142/S0219635207001374, 17472227.
66. Silverstein SM, Jaeger J, Lepore D, Wilkniss SM, Savitz A, Malinovsky I, Hawthorne D, Raines S, Carson S, Marcello S, Zukin SR, Furlong S, Dent G. A comparative study of the MATRICS and IntegNeuro cognitive assessment batteries. J Clin Exp Neuropsychol 2010, 7:1-16.
67. Williams LM, Whitford TJ, Flynn G, Wong W, Liddell BJ, Silverstein S, Galletly C, Harris AW, Gordon E. General and social cognition in first episode schizophrenia: Identification of separable factors and prediction of functional outcome using the IntegNeuro test battery. Schizophr Res 2008, 99:182-191. 10.1016/j.schres.2007.10.019, 18053688.
68. Williams LM, Hermens DF, Thein T, Clark CR, Cooper NJ, Clarke SD, Lamb C, Gordon E, Kohn MR. Using brain-based cognitive measures to support clinical decisions in ADHD. Pediatr Neurol 2010, 42:118-126. 10.1016/j.pediatrneurol.2009.08.010, 20117748.
69. Wong KKH, Grunstein RR, Bartlerr DJ, Gordon E. Brain function in obstructive sleep apnea: results from the Brain Resource International Database. J Integr Neurosci 2006, 5(1):111-121. 10.1142/S0219635206001033, 16544369.
70. Davidson RJ. Anterior electrophysiological asymmetries, emotion, and depression: Conceptual and methodological conundrums. Psychophysiol 1998, 35:607-614.
71. Allen JJB, Urry HL, Hitt SK, Coan JA. Stability of Resting Frontal EEG Asymmetry Across Different Clinical States of Depression. Psychophysiology 2004, 41:269-280. 10.1111/j.1469-8986.2003.00149.x, 15032992.
72. Kemp AH, Hopkinson PJ, Hermens DF, Rowe DL, Sumich AL, Clark CR, Drinkenburg W, Abdi N, Penrose R, McFarlane A, Boyce P, Gordon E, Williams LM. Fronto-temporal alterations within the first 200 ms during an attentional task distinguish major depression, non-clinical participants with depressed mood and healthy controls: A potential biomarker?. Hum Brain Mapp 2009, 30(2):602-614. 10.1002/hbm.20528, 18181154.
73. Task Force of the European Society of Cardiology the North American Society of Pacing Electrophysiology Heart rate variability: standards of measurement, physiological interpretation and clinical use. Circulation 1996, 93:1043-1065. Task Force of the European Society of Cardiology the North American Society of Pacing Electrophysiology.
74. Brain Resource Data Quality Control Manual 2010, Ultimo: Brain Resource Ltd.
75. Kobak KA, Williams JB, Engelhardt N. A comparison of face-to-face and remote assessment of inter-rater reliability on the Hamilton Depression Rating Scale via videoconferencing. Psychiatry Res 2008, 158(1):99-103. 10.1016/j.psychres.2007.06.025, 17961715.